Health-care companies rose as traders bet the sector would fare better than other sectors if inflation remained strong.
Investors' concerns have flipped to inflation from banking weakness as a wave of bank runs appears to have abated and economic data exhibits surprising resilience.
Inflation expectations in the U.S., eurozone and the United Kingdom have moderated, but still foreshadow price growth ahead of central-bank targets, said economists at brokerage JPMorgan.
Scynexis shares surged after British drug giant GSK licensed one of its gynecological-condition treatments.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
03-30-23 1656ET
